Sign In
Last checked at 
8 Apr 2015 08:18
Hutchison China MediTech Limited ("Chi-Med")
(AIM: HCM)
Directors' Shareholding
London: Wednesday, 8 April 2015: Chi-Med received notifications on 8 April 2015 that the following Directors have purchased ordinary shares of US$1.00 each in Chi-Med (the "Shares") as follows:-
Director | Date of purchase | Number of Shares purchased | Purchase price | Beneficial interest in Shares following purchases
| |
Number of Shares | % of total issued share capital | ||||
Simon To (Executive Director and Chairman)
| 2 April 2015
7 April 2015 | 10,000
48,000 | GBP13.85
GBP13.85 | 127,000 | 0.24% |
Edith Shih (Non-executive Director and Company Secretary) | 2 April 2015
7 April 2015 | 10,000
2,000 | GBP13.85
GBP13.85 | 60,000 | 0.11% |
Ends
Enquiries
Chi-Med Christian Hogg, CEO | Telephone: +852 2121 8200 |
Panmure Gordon (UK) Limited Richard Gray Andrew Potts | Telephone: +44 20 7886 2500 |
Citigate Dewe Rogerson Anthony Carlisle David Dible | Telephone: +44 20 7638 9571Mobile: +44 7973 611 888Mobile: +44 7967 566 919 |
About Chi-Med
Chi-Med is a China-based healthcare group focused on researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products. Its Drug R&D Division focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases. Its China Healthcare Division manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China. Its emerging Consumer Products Division focuses on organic and natural consumer products in Asia.
Chi-Med is majority owned by the multinational conglomerate Hutchison Whampoa Limited (SEHK:13). For more information, please visit: www.chi-med.com.
Follow the stocks
